The preparations for the CBD epilepsy study were started in December 2018, including hiring a fulltime research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. We anticipated enrolling 20 patients per year; therefore, we are on track with 54 patients in 2 1/2 years.
Research Update Mid-year 2 CHF 02323: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy
Research Update from Dr. Stephanie McGrath looking at use of CBD for the treatment of epilepsy.
Research Update Mid-Year-3 CHF-02252: Investigating a Ketogenic Medium-Chain Triglyceride (MCT) Supplement for the Treatment of Drug-Resistant Canine Idiopathic Epilepsy and Its Behavioral Comorbidities
Research Update from Dr. Volk for supplemental treatment of epilepsy.
Research Update Mid-Year 1 for Identification of Genetic Risk Factors for Canine Epilepsy
Research update for Dr. Johnson’s work looking to identify possible genetic risk factors for canine epilepsy.
Research Update Mid-Year 1 for ketogenic MCT supplement therapy use in treating idiopathic canine epilepsy
Update on progress of Dr. Volk’s work looking at the benefits of using a ketogenic MCT supplement to aid in treatment of dogs with idiopathic canine epilepsy.
